Batra, Ranjan
Nelles, David A.
Roth, Daniela M.
Krach, Florian
Nutter, Curtis A.
Tadokoro, Takahiro http://orcid.org/0000-0003-4884-0247
Thomas, James D. http://orcid.org/0000-0002-8893-6350
Sznajder, Ćukasz J. http://orcid.org/0000-0001-6822-6485
Blue, Steven M.
Gutierrez, Haydee L.
Liu, Patrick
Aigner, Stefan
Platoshyn, Oleksandr http://orcid.org/0000-0001-6529-6752
Miyanohara, Atsushi
Marsala, Martin http://orcid.org/0000-0001-5048-6422
Swanson, Maurice S. http://orcid.org/0000-0001-6245-5367
Yeo, Gene W. http://orcid.org/0000-0002-0799-6037
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS103172, NS103172, NS103172, NS103172, NS103172, NS103172, NS103172, NS103172, NS103172, NS103172)
Muscular Dystrophy Association (MVP575855, MVP575855, MVP575855)
Locana, Inc. is a privately funded biotechnology start up in San Digeo.
Article History
Received: 13 May 2019
Accepted: 10 August 2020
First Online: 14 September 2020
Competing interests
: G.W.Y. is a cofounder, member of the board of directors, equity holder and paid consultant of Locanabio. D.A.N. is a cofounder and an equity holder of Locanabio. R.B. is an equity holder and employee of Locanabio. M.S.S. is an equity holder of Locanabio and a Scientific Advisory Board member of Skyhawk Therapeutics. The terms of this arrangement have been reviewed and approved by the University of California San Diego and the University of Florida, Gainesville in accordance with their conflict of interest policies. The other authors declare no other competing interests.